SNOA Sonoma Pharmaceuticals
- 0.1613
- +0.0023+1.45%
Sonoma Pharmaceuticals News
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Sonoma Pharmaceuticals Presents Business and Financial Update
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
BOULDER, CO / ACCESSWIRE / April 9, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn technology based stabilized hypochlorous acid
Sonoma Pharmaceuticals Reports Recent Publication From Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
BOULDER, CO / ACCESSWIRE / April 4, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn technology based stabilized hypochlorous ac
Sonoma Pharmaceuticals Outlines Growth and Challenges
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
BOULDER, CO / ACCESSWIRE / March 28, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn technology based stabilized hypochlorous acid
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) shares rose 328.2% to $20.34 during Thursday's pre-market session. The company's market cap stands at $16.3 million. Xilio Therapeutics (NASDAQ:XLO) stock moved
Sonoma Pharmaceuticals Highlights Safety Advantages of Its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
BOULDER, CO / ACCESSWIRE / March 27, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn technology based stabilized hypochlorous a
Sonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Sonoma Pharmaceuticals Q3 EPS $(0.08) Up From $(0.62) YoY, Sales $3.14M Up From $2.94M YoY
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported quarterly losses of $(0.08) per share. This is a 87.1 percent increase over losses of $(0.62) per share from the same period last year. The company repor
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
Revenues increased 7% compared to quarter from prior year and 15% from prior quarterImprovement in gross margin for quarter of 19% compared to prior yearImprovement in net loss for quarter of $1.0 mil
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersKura Oncology (NASDAQ:KURA) stock rose 39.6% to $18.73 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.3 billion. Redhill Biopharma (NASDAQ:RDHL) st
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use
BOULDER, CO / ACCESSWIRE / January 23, 2024 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn technology based stabilized hypochlorous acid
Marijuana Reclassification And DEA: Congressional Report Outlines Rescheduling Limits
The U.S. Drug Enforcement Administration (DEA) might finally budge on it is decades-long cannabis criminalization, but don't hold your breath for legal weed shops just yet.
12 Health Care Stocks Moving In Monday's Intraday Session
GainersAtreca (NASDAQ:BCEL) stock rose 52.7% to $0.36 during Monday's regular session. The market value of their outstanding shares is at $14.1 million. Cyclo Therapeutics (NASDAQ:CYTH) shares rose 29
NovaBay Pharmaceuticals And Sonoma Pharmaceuticals Agree To Market Avenova-Branded Products In European Union; Sonoma Will Manufacture Ocudox And Pay NovaBay Royalty Fee Based On Net Product Sales
The new products will combine Sonoma's existing eye product Ocudox, which has already received a Class IIB CE mark for sale in the European Union, with Avenova branding, and are expected to be markete
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersAllarity Therapeutics (NASDAQ:ALLR) shares rose 44.0% to $0.86 during Tuesday's pre-market session. The company's market cap stands at $3.9 million. Sonoma Pharmaceuticals (NASDAQ:SNOA) stock r
Sonoma Pharmaceuticals GAAP EPS of -$0.29 Misses by $0.05, Revenue of $2.73M Misses by $0.75M
Sonoma Pharmaceuticals Q2 EPS $(0.29) Misses $(0.24) Estimate, Sales $2.73M Miss $3.48M Estimate
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.24) by 20.83 percent. This is a 12.12 percent increase over losse
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
Gross profit percentage of 36% for the quarter, up 1% from first fiscal quarter 2024Total operating expenses decreased for the quarter and six months ended September 30, 2023 compared to same period p
Analysis
Price Target
No Data
